Information Provided By: 
Fly News Breaks for March 1, 2017
IPXL
Mar 1, 2017 | 15:48 EDT
BMO Capital analyst Gary Nachman said Impax had a "challenging" Q4 and the fact that the company declined to give revenue and EPS guidance for 2017 leaves many questions unanswered. The analyst, who also said it was disappointing to hear about delays to several key generics and that the company's gross margin guidance came in light, lowered his price target on Impax shares to $13 from $18 and keeps a Market Perform rating on the stock.
News For IPXL From the Last 2 Days
There are no results for your query IPXL
